Alzheimer's disease (AD) is an age-related dementia and presents a growing medical and economic burden. AD is classically diagnosed via the accumulation and aggregation of amyloid-β and tau. Potential and FDA-approved therapies designed to clear these aggregates at best delay rather than prevent disease, indicating that the root cause of AD lay upstream of aggregate formation. Tau protein's phosphorylation is critical for AD progression, and phosphorylation at Threonine 231 is thought to be an early disease-associated, “gatekeeper” event.
Objective
Previously, we showed that genomic, single-copy insertion of phosphomimetic human tau (T231E) into C. elegans mechanosensory neurons induced age-dependent deficits in light-touch sensation. Herein, we aimed to determine whether T231E tau could preferentially impact unique neuronal subclasses and whether observed deficits could be reversed via tau clearance.
Methods
We generated novel C. elegans models which express pan-neuronal human tau tagged with an auxin inducible degron and utilized an assortment of behavioral assays to assess whether specific neuronal behaviors might be impacted preferentially and whether any observed deficits could be reversed with age.
Results
Despite our hypothesis that prolonged stress in older animals would induce irreversible metabolic rewiring or maladaptation, tau depletion rescued deficits in the behavioral response to light touch at all ages tested, including in old worms which displayed the most overt phenotypes.
Conclusions
Our data suggests that C. elegans mechanosensory neurons are preferentially impacted by T231E, and that neuronal dysfunction induced by phosphorylated tau is reversible. This provides reassurance that current therapeutic efforts aimed at reducing soluble tau levels may prove effective.
CummingsJZhouYLeeG, et al.Alzheimer's disease drug development pipeline: 2024. Alzheimers Dement (N Y)2024; 10: e12465.
3.
HeidebrinkJLPaulsonHL. Lessons learned from approval of aducanumab for Alzheimer's disease. Ann Rev Med2024; 75: 99–111.
4.
ImbimboBPIppatiSWatlingM, et al.A critical appraisal of tau-targeting therapies for primary and secondary tauopathies. Alzheimers Dement2022; 18: 1008–1037.
5.
SelfWKHoltzmanDM. Emerging diagnostics and therapeutics for Alzheimer disease. Nat Med2023; 29: 2187–2199.
6.
WesselingHMairWKumarM, et al.Tau PTM profiles identify patient heterogeneity and stages of Alzheimer’s disease. Cell2020; 183: 1699–1713.e1613.
7.
JeganathanSHascherAChinnathambiS, et al.Proline-directed pseudo-phosphorylation at AT8 and PHF1 epitopes induces a compaction of the paperclip folding of tau and generates a pathological (MC-1) conformation. J Biol Chem2008; 283: 32066–32076.
8.
SchwalbeMKadavathHBiernatJ, et al.Structural impact of tau phosphorylation at threonine 231. Structure2015; 23: 1448–1458.
9.
ChoJHJohnsonGV. Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau's ability to bind and stabilize microtubules. J Neurochem2004; 88: 349–358.
10.
Aragão GomesLUytterhoevenVLopez-SanmartinD, et al.Maturation of neuronal AD-tau pathology involves site-specific phosphorylation of cytoplasmic and synaptic tau preceding conformational change and fibril formation. Acta Neuropathol2021; 141: 173–192.
11.
DespresCByrneCQiH, et al.Identification of the tau phosphorylation pattern that drives its aggregation. Proc Natl Acad Sci U S A2017; 114: 9080–9085.
12.
Luna-MuñozJChávez-MacíasLGarcía-SierraF, et al.Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer's disease. J Alzheimers Dis2007; 12: 365–375.
13.
MoszczynskiAJGoharMVolkeningK, et al.Thr175-phosphorylated tau induces pathologic fibril formation via GSK3β-mediated phosphorylation of Thr231 in vitro. Neurobiol Aging2015; 36: 1590–1599.
14.
AshtonNJBenedetALPascoalTA, et al.Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease. EBioMedicine2022; 76: 103836.
15.
GuhaSFischerSJohnsonGVW, et al.Tauopathy-associated tau modifications selectively impact neurodegeneration and mitophagy in a novel C. elegans single-copy transgenic model. Mol Neurodegener2020; 15: 65.
16.
YeminiELinANejatbakhshA, et al.NeuroPAL: a multicolor atlas for whole-brain neuronal identification in C. elegans. Cell2021; 184: 272–288.e211.
17.
BrennerS. The genetics of Caenorhabditis elegans. Genetics1974; 77: 71–94.
18.
StiernagleT. Maintenance of C. elegans. In: The C. elegans Research Community. (eds) Wormbook: the online review of C. elegans biology. Pasadena, CA: WormBook, 2006, pp.1–11.
Frøkjær-JensenCWayne DavisMHopkinsCE, et al.Single-copy insertion of transgenes in Caenorhabditis elegans. Nat Genet2008; 40: 1375–1383.
21.
StevensonZCMoerdyk-SchauweckerMJJamisonB, et al.Rapid self-selecting and clone-free integration of transgenes into engineered CRISPR safe harbor locations in C. elegans. G3 (Bethesda)2020; 10: 3775–3782.
22.
PaixAFolkmannARasolosonD, et al.High efficiency, homology-directed genome editing in Caenorhabditis elegans using CRISPR-Cas9 ribonucleoprotein complexes. Genetics2015; 201: 47–54.
23.
KimHIshidateTGhantaKS, et al.A Co-CRISPR strategy for efficient genome editing in Caenorhabditis elegans. Genetics2014; 197: 1069–1080.
24.
El MouridiSAlkhaldiFFrøkjær-JensenC. Modular safe-harbor transgene insertion for targeted single-copy and extrachromosomal array integration in Caenorhabditis elegans. G3 (Bethesda)2022; 12: jkac184.
25.
ChenXChalfieM. Modulation of C. elegans touch sensitivity is integrated at multiple levels. J Neurosci2014; 34: 6522–6536.
26.
Nussbaum-KrammerCINetoMFBrielmannRM, et al.Investigating the spreading and toxicity of prion-like proteins using the metazoan model organism C. elegans. J Vis Exp2015; 95: 52321.
27.
JaverACurrieMLeeCW, et al.An open-source platform for analyzing and sharing worm-behavior data. Nat Methods2018; 15: 645–646.
28.
CaoSQWangHLPalikarasK, et al.Chemotaxis assay for evaluation of memory-like behavior in wild-type and Alzheimer's-disease-like C. elegans models. STAR Protoc2023; 4: 102250.
29.
NataleCBarzagoMMDiomedeL. Caenorhabditis elegans models to investigate the mechanisms underlying tau toxicity in tauopathies. Brain Sci2020; 10: 838.
30.
WangCSaarVLeungKL, et al.Human amyloid β peptide and tau co-expression impairs behavior and causes specific gene expression changes in Caenorhabditis elegans. Neurobiol Dis2018; 109: 88–101.
31.
MiyasakaTShinzakiYYoshimuraS, et al.Imbalanced expression of tau and tubulin induces neuronal dysfunction in C. elegans models of tauopathy. Front Neurosci2018; 12: 415.
32.
BuchholzSZempelH. The six brain-specific TAU isoforms and their role in Alzheimer's disease and related neurodegenerative dementia syndromes. Alzheimers Dement2024; 20: 3606–3628.
33.
AshleyGEDuongTLevensonMT, et al.An expanded auxin-inducible degron toolkit for Caenorhabditis elegans. Genetics2021; 217: iyab006.
34.
BessaCMacielPRodriguesA. Using C. elegans to decipher the cellular and molecular mechanisms underlying neurodevelopmental disorders. Mol Neurobiol2013; 48: 465–489.
35.
GuhaSChengACarrollT, et al.Selective disruption of Drp1-independent mitophagy and mitolysosome trafficking by an Alzheimer’s disease relevant tau modification in a novel Caenorhabditis elegans model. Genetics2022; 222: iyac104.
36.
JaverARipoll-SánchezLBrownAEX. Powerful and interpretable behavioural features for quantitative phenotyping of Caenorhabditis elegans. Philos Trans R Soc Lond B Biol Sci2018; 373: 20170375.
37.
VoglisGTavernarakisN. A synaptic DEG/ENaC ion channel mediates learning in C. elegans by facilitating dopamine signalling. EMBO J2008; 27: 3288–3299.
38.
FangEFHouYPalikarasK, et al.Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease. Nat Neurosci2019; 22: 401–412.
39.
AghayevaUBhattacharyaASuralS, et al.DAF-16/FoxO and DAF-12/VDR control cellular plasticity both cell-autonomously and via interorgan signaling. PLOS Biol2021; 19: e3001204.
40.
DhondtIPetyukVABauerS, et al.Changes of protein turnover in aging Caenorhabditis elegans. Mol Cell Proteomics2017; 16: 1621–1633.
41.
GuhaSFischerSChengA, et al.A T231E mutant that mimics pathologic phosphorylation of tau in Alzheimer's disease causes activation of the mitochondrial unfolded protein response in C. elegans touch neurons. MicroPubl Biol2020; 2020. 10.17912/micropub.biology.000306
42.
SantacruzK. Tau suppression in a neurodegenerative mouse model improves memory function. Science2005; 309: 476–481.
43.
MroczkoBGroblewskaMLitman-ZawadzkaA. The role of protein misfolding and tau oligomers (TauOs) in Alzheimer’s disease (AD). Int J Mol Sci2019; 20: 4661.
44.
AugustinackJCSchneiderAMandelkowE-M, et al.Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol2002; 103: 26–35.
45.
MiKJohnsonGV. The role of tau phosphorylation in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res2006; 3: 449–463.
46.
JanelidzeSMattssonNPalmqvistS, et al.Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nat Med2020; 26: 379–386.
47.
JanelidzeSPalmqvistSLeuzyA, et al.Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau. Alzheimers Dement2022; 18: 283–293.
48.
NeddensJTemmelMFlunkertS, et al.Phosphorylation of different tau sites during progression of Alzheimer’s disease. Acta Neuropathol Commun2018; 6: 52.
49.
BraakHBraakE. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol1991; 82: 239–259.
50.
FuHPossentiAFreerR, et al.A tau homeostasis signature is linked with the cellular and regional vulnerability of excitatory neurons to tau pathology. Nat Neurosci2019; 22: 47–56.
51.
EspíndolaSLDamianichAAlvarezRJ, et al.Modulation of tau isoforms imbalance precludes tau pathology and cognitive decline in a mouse model of tauopathy. Cell Rep2018; 23: 709–715.
52.
KraemerBCZhangBLeverenzJB, et al.Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy. Proc Natl Acad Sci U S A2003; 100: 9980–9985.
53.
Aquino NunezWCombsBGamblinTC, et al.Age-dependent accumulation of tau aggregation in Caenorhabditis elegans. Front Aging2022; 3: 928574.
54.
SchaferWR. Mechanosensory molecules and circuits in C. elegans. Pflügers Archiv2015; 467: 39–48.
55.
LengKLiEEserR, et al.Molecular characterization of selectively vulnerable neurons in Alzheimer’s disease. Nat Neurosci2021; 24: 276–287.
56.
EisnerVPicardMHajnóczkyG. Mitochondrial dynamics in adaptive and maladaptive cellular stress responses. Nat Cell Biol2018; 20: 755–765.
57.
QuintanillaRAvon BernhardiRGodoyJA, et al.Phosphorylated tau potentiates Aβ-induced mitochondrial damage in mature neurons. Neurobiol Dis2014; 71: 260–269.
58.
PérezMJVergara-PulgarKJaraC, et al.Caspase-cleaved tau impairs mitochondrial dynamics in Alzheimer's disease. Mol Neurobiol2018; 55: 1004–1018.
59.
CaiQTammineniP. Alterations in mitochondrial quality control in Alzheimer’s disease. Front Cell Neurosci2016; 10: 24.
60.
ShpilkaTHaynesCM. The mitochondrial UPR: mechanisms, physiological functions and implications in ageing. Nat Rev Mol Cell Biol2018; 19: 109–120.
61.
LinYFSchulzAMPellegrinoMW, et al.Maintenance and propagation of a deleterious mitochondrial genome by the mitochondrial unfolded protein response. Nature2016; 533: 416–419.
62.
RobersonEDScearce-LevieKPalopJJ, et al.Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science2007; 316: 750–754.
63.
DeVosSLMillerRLSchochKM, et al.Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med2017; 9: eaag0481.
64.
CongdonEEJiCTetlowAM, et al.Tau-targeting therapies for Alzheimer disease: current status and future directions. Nat Rev Neurol2023; 19: 715–736.
65.
SakamotoKSohZSuzukiM, et al.Forward and backward locomotion patterns in C. elegans generated by a connectome-based model simulation. Sci Rep2021; 11: 13737.
TheunisCCrespo-BielNGafnerV, et al.Efficacy and safety of a liposome-based vaccine against protein tau, assessed in tau P301L mice that model tauopathy. PLoS One2013; 8: e72301.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
